Embracing Diversity & Inclusion

1. 9 Factors For Driving Inclusivity & Patient Centricity In A Transformed Clinical Trials Landscape 9/15/2020

   Patient-centricity, quality, and inclusion are not natural consequences of the shift to virtual clinical trials. To be intentional with the design, we must start with articulating and understanding the full contexts of patients’ lives, medical and beyond.

2. How FDA Is Helping Advance Clinical Trial Diversity 9/1/2020

   An update from the FDA Office of Minority Health and Health Equity on its efforts to address health disparities and health equity — and ultimately strengthen the agency’s ability to respond to minority health concerns.

3. How Can We Begin To Solve Unconscious Systemic Bias In Clinical Trials? 8/4/2020

   Halting disparities in clinical trials during the time of COVID-19 will take eradicating unconscious bias, building trust in diverse communities, dispelling long-held myths, constructing relationships, and educating patients, family members, and physicians.

4. 6 Practical Ways To Increase Diversity In Clinical Trials 6/11/2020

   Even when a certain disease is more prevalent in a particular minority population, it can still be difficult for trial investigators to reach the right individuals. As an industry — as a group of researchers dedicating our lives to improve the health of others, regardless of their race, age, gender, or disease — how can we do better?

5. Diverse Enrollment In Clinical Trials: What Do Successful Research Sites Have In Common? 5/19/2020

   Diverse enrollment in clinical research studies is a complex issue that has multifaceted implications for clinical research sites. An understanding of the research site community’s perceived awareness and current ability to enroll these populations is lacking in the clinical trials landscape.

6. How Do Underserved Communities Prefer To Learn About Clinical Research? 5/5/2020

   It is important to look at the big picture and better understand core participation motivators and barriers from the underrepresented patient’s perspective in order to better enable access to and increase their participation in clinical trials.

7. Bridging The Chasm Between The Haves And The Have-Nots In Cancer Trials 4/9/2020

   Clinical trials are the most important and reliable means available to provide scientific evidence for developing therapies and effective care management for patients. It is therefore essential to achieve diverse participation in clinical trials in order to ensure medical advancements — whether for testing or treating COVID-19 or for cancer therapeutics — are applicable to all populations.

8. 4 Questions AbbVie Asked To Create More Diverse Clinical Trials 1/17/2020

   Over the five years I have been at AbbVie, the idea of diversity and inclusivity in healthcare was especially relevant to our clinical trials in uterine fibroids. We successfully centered patients in our program by understanding their needs, concerns, and desires, which enabled us to recruit and retain women representative of the patient landscape in this disease state. How? We asked ourselves four important questions.